Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Remix Therapeutics
Biotech
Spurned by FDA, Passage Bio finds exit through Remix
The proposed merger was announced in conjunction with an approximately $100 million private placement, and grants Remix a place on the Nasdaq.
Darren Incorvaia
Jun 24, 2026 5:20pm
Former Roche oncology head turns to Tubulis—Chutes & Ladders
Jan 9, 2026 8:30am
Ex-Eisai leader to be new NextPoint CEO—Chutes & Ladders
Feb 2, 2024 9:30am
Get ready for the Roche (Remix), a $30M small molecule deal
Jan 3, 2024 7:00am
New year, new C-suite execs—Chutes & Ladders
Jan 6, 2023 9:30am
Alchemab CEO resigns citing 'personal reasons'—Chutes & Ladders
May 27, 2022 9:30am
